Hostname: page-component-7c8c6479df-ph5wq Total loading time: 0 Render date: 2024-03-27T03:04:12.630Z Has data issue: false hasContentIssue false

Recommendations for Surveillance of Clostridium difficile–Associated Disease

Published online by Cambridge University Press:  02 January 2015

L. Clifford McDonald*
Affiliation:
Centers for Disease Control and Prevention, Atlanta, Georgia
Bruno Coignard
Affiliation:
Institut de Veille Sanitaire, Saint-Maurice Cedex, France
Erik Dubberke
Affiliation:
Washington University School of Medicine, St. Louis, Missouri
Xiaoyan Song
Affiliation:
Johns Hopkins Medical Institution, Baltimore, Maryland
Teresa Horan
Affiliation:
Centers for Disease Control and Prevention, Atlanta, Georgia
Preeta K. Kutty
Affiliation:
Centers for Disease Control and Prevention, Atlanta, Georgia
*
1600 Clifton Rd., MS A35, Atlanta, GA 30333 (cmcdonaldl@cdc.gov)

Abstract

Background.

The epidemiology of Clostridium difficile-associated disease (CDAD) is changing, with evidence of increased incidence and severity. However, the understanding of the magnitude of and reasons for this change is currently hampered by the lack of standardized surveillance methods.

Objective and Methods.

An ad hoc C. difficile surveillance working group was formed to develop interim surveillance definitions and recommendations based on existing literature and expert opinion that can help to improve CDAD surveillance and prevention efforts.

Definitions and Recommendations.

A CDAD case patient was defined as a patient with symptoms of diarrhea or toxic megacolon combined with a positive result of a laboratory assay and/or endoscopic or histopathologic evidence of pseudomembranous colitis. Recurrent CDAD was defined as repeated episodes within 8 weeks of each other. Severe CDAD was defined by CDAD-associated admission to an intensive care unit, colectomy, or death within 30 days after onset. Case patients were categorized by the setting in which C. difficile was likely acquired, to account for recent evidence that suggests that healthcare facility-associated CDAD may have its onset in the community up to 4 weeks after discharge. Tracking of healthcare facility–onset, healthcare facility–associated CDAD is the minimum surveillance required for healthcare settings; tracking of community–onset, healthcare facility–associated CDAD should be performed only in conjunction with tracking of healthcare facility–onset, healthcare facility–associated CDAD. Community–associated CDAD was defined by symptom onset more than 12 weeks after the last discharge from a healthcare facility. Rates of both healthcare facility–onset, healthcare facility–associated CDAD and community–onset, healthcare facility–associated CDAD should be expressed as case patients per 10,000 patient–days; rates of community-associated CDAD should be expressed as case patients per 100,000 person-years.

Type
Original Articles
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Bartlett, JG. Clinical practice: antibiotic-associated diarrhea. N Engl J Med 2002;346:334339.CrossRefGoogle ScholarPubMed
2.Bauer, TM, Lalvani, A, Fehrenbach, J, et al. Derivation and validation of guidelines for stool cultures for enteropathogenic bacteria other than Clostridium difficile in hospitalized adults. JAMA 2001;285:313319.Google Scholar
3.Johnson, S, Samore, MH, Farrow, KA, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999;341:16451651.Google Scholar
4.Dallai, RM, Harbrecht, BG, Boujoukas, AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002;235:363372.CrossRefGoogle Scholar
5.Pepin, J, Valiquette, L, Cossette, B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005;173:10371042.CrossRefGoogle ScholarPubMed
6.Muto, CA, Pokrywka, M, Shutt, K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273280.CrossRefGoogle Scholar
7.McDonald, LC, Killgore, GE, Thompson, A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:24332441.CrossRefGoogle ScholarPubMed
8.McDonald, LC. Clostridium difficile, responding to a new threat from an old enemy. Infect Control Hosp Epidemiol 2005;26:672675.CrossRefGoogle ScholarPubMed
9.Palmore, TN, Sohn, S, Malak, SF, Eagan, J, Sepkowitz, KA. Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect Control Hosp Epidemiol 2005;26:680684.Google Scholar
10.Sohn, S, Climo, M, Diekema, D, et al. Varying rates of Clostridium difficile-associated diarrhea at prevention epicenter hospitals. Infect Control Hosp Epidemiol 2005;26:676679.CrossRefGoogle ScholarPubMed
11.Olson, MM, Shanholtzer, CJ, Lee, JT Jr, Gerding, DN. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 1994;15:371381.CrossRefGoogle ScholarPubMed
12.Johal, SS, Hammond, J, Solomon, K, James, PD, Mahida, YR. Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut 2004;53:673677.CrossRefGoogle ScholarPubMed
13.Archibald, LK, Banerjee, SN, Jarvis, WR. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. Infect Dis 2004;189:15851589.CrossRefGoogle ScholarPubMed
14.Miller, MA, Hyland, M, Ofner-Agostini, M, Gourdeau, M, Ishak, M. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 2002;23:137140.CrossRefGoogle ScholarPubMed
15.Miller, MA, Gravel, D, Mulvey, M, et al. Surveillance for nosocomial Clostridium difficile associated diarrhea (N-CDAD) within acute-care hospitals in Canada: results of the 2005 nosocomial infections surveillance program (CNISP) study shows escalating mortality. In: Program and abstracts of the 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America;March 18-21, 2006;Chicago, IL. Abstract 151.Google Scholar
16.Hirschhorn, LR, Trnka, Y, Onderdonk, A, Lee, ML, Platt, R. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 1994;169:127133.CrossRefGoogle ScholarPubMed
17.Levy, DG, Stergachis, A, McFarland, LV, et al. Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting. Clin Ther 2000;22:91102.CrossRefGoogle ScholarPubMed
18.Karlstrom, O, Fryklund, B, Tullus, K, Burman, LG. A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. The Swedish C. difficile Study Group. Clin Infect Dis 1998;26:141145.Google Scholar
19.Noren, T, Akerlund, T, Back, E, et al. Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county. J Clin Microbiol 2004;42:36353643.Google Scholar
20.Dial, S, Delaney, JA, Barkun, AN, Suissa, S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294:29892995.CrossRefGoogle ScholarPubMed
21.Severe Clostridium difficile-associated disease in populations previously at low risk—four states, 2005. MMWR Morb Mortal Wkly Rep 2005;54:12011205.Google Scholar
22.Chang, H, Parada, J, Evans, C, Johnson, S, Gerding, DN. Onset of symptoms and time to diagnosis of Clostridium difficile diarrhea among outpatients discharged from an acute care hospital. In: Program and abstracts of the 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America;March 18-21, 2006; Chicago, IL. Abstract 154.Google Scholar
23.McDonald, J, Naggie, S, Kuhn, L, et al. Community-onset Clostridium difficile-associated diarrhea: a tale of two medical centers. In: Program and abstracts of the 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America;March 18-21, 2006; Chicago, IL. Abstract 181.Google Scholar
24.Mayfield, J, McMullen, K, Dubberke, E. Comparison of Clostridium difficile-associated disease rates using a traditional vs. expanded definition. In: Program and abstracts of the 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America;March 18-21, 2006;Chicago, IL. Abstract 180.Google Scholar
25.McFarland, LV, Mulligan, ME, Kwok, RY, Stamm, WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320:204210.CrossRefGoogle ScholarPubMed
26.Samore, MH, DeGirolami, PC, Tlucko, A, Lichtenberg, DA, Melvin, ZA, Karchmer, AW. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis 1994;18:181187.CrossRefGoogle ScholarPubMed
27.Walker, KJ, Gilliland, SS, Vance-Bryan, K, et al. Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. J Am Geriatr Soc 1993;41:940946.Google Scholar
28.Rivera, EV, Woods, S. Prevalence of asymptomatic Clostridium difficile colonization in a nursing home population: a cross-sectional study. J Gend Specif Med 2003;6:2730.Google Scholar
29.Clabots, CR, Johnson, S, Olson, MM, Peterson, LR, Gerding, DN. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 1992;166: 561-567.CrossRefGoogle ScholarPubMed
30.Ozaki, E, Kato, H, Kita, H, et al. Clostridium difficile colonization in healthy adults: transient colonization and correlation with enterococcal colonization. J Med Microbiol 2004;53:167172.Google Scholar
31.Iizuka, M, Konno, S, Itou, H, et al. Novel evidence suggesting Clostridium difficile is present in human gut microbiota more frequently than previously suspected. Microbiol Immunol 2004;48:889892.CrossRefGoogle ScholarPubMed
32.Viscidi, R, Willey, S, Bartlett, JG. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 1981;81:59.CrossRefGoogle ScholarPubMed
33.Aronsson, B, Mollby, R, Nord, CE. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982. J Infect Dis 1985;151:476481.Google Scholar
34.Matsuki, S, Ozaki, E, Shozu, M, et al. Colonization by Clostridium difficile of neonates in a hospital, and infants and children in three day-care facilities of Kanazawa, Japan. Int Microbiol 2005;8:4348.Google Scholar
35.Kyne, L, Warny, M, Qamar, A, Kelly, CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342:390397.Google Scholar
36.Kyne, L, Warny, M, Qamar, A, Kelly, CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001;357:189193.Google Scholar
37.Shim, JK, Johnson, S, Samore, MH, Bliss, DZ, Gerding, DN. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998;351:633636.CrossRefGoogle ScholarPubMed
38.Sambol, SP, Merrigan, MM, Tang, JK, Johnson, S, Gerding, DN. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis 2002;186:17811789.CrossRefGoogle ScholarPubMed
39.Johnson, S, Clabots, CR, Linn, FV, Olson, MM, Peterson, LR, Gerding, DN. Nosocomial Clostridium difficile colonisation and disease. Lancet 1990;336:97100.Google Scholar
40.Anand, A, Bashey, B, Mir, T, Glatt, AE. Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am J Gastroenterol 1994;89:519523.Google Scholar